Literature DB >> 8699236

Intra arterial chemotherapy with ACNU and radiotherapy in inoperable malignant gliomas.

L Chauveinc1, M T Sola-Martinez, M Martin-Duverneuil, J J Mazeron, T Faillot, P Cornu, L Capelle, J Y Delattre, M Poisson, F Baillet, J Chiras.   

Abstract

For the non-operable malignant glioma patients, prognosis remains poor, with a survival of 8 months for the glioblastomas (G), and 15 months for anaplastic astrocytomas (AA). 27 histologic proven malignant gliomas (17 AA and 10 G) were treated between April 1991 and June 1992. Median age was 48 years. The therapeutic protocol consisted of three courses of intra arterial chemotherapy (IAC) with ACNU, at intervals of six weeks, and a localised 60 Gy radiotherapy between the first and the second IAC course. 72 courses of IAC were delivered (2.4 per patient). Response rate was 51.8%. Median survival (MS) was 13 months, with a survival rate of 28% at 24 months. For the AA, MS was 21 months, with a survival rate of 37% at 24 months. For the G, median survival was 10 months. Responders were 65% for AA, 30% for G. Non responders all died before 24 months had relapsed with a MS of 9 months. 54% of responding patients had a 2 years survival. Toxicity were acceptable with 7% of haematological toxicity and partial loss of visual acuity in 11% of the case. No chronic neurological sequellae were noted. We compare theses results with two previous trials, concerning inoperable patients, treated by association of radiotherapy and systemic chemotherapy. Survival seems to be equivalent with HeCNU and with this treatment, but toxicity decrease with ACNU. Early radiotherapy does not increase complications. This treatment can be used for patients with inoperable malignant gliomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699236     DOI: 10.1007/bf00177477

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

Review 1.  [Indications for radiotherapy in intracranial and intraspinal tumors in adults (Except pituitary tumors)].

Authors:  J P Constans; M Schlienger
Journal:  Neurochirurgie       Date:  1975-06       Impact factor: 1.553

2.  Combined intraarterial and systemic chemotherapy for intracerebral tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; N Russell; M Richard; B Benoit
Journal:  Neurosurgery       Date:  1987-08       Impact factor: 4.654

3.  Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.

Authors:  P Pouillart; G Mathe; T H Thy; J Lheritier; M Poisson; P Huguenin; H Gauthier; P Morin; R Parrot
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

4.  Intra-arterial ACNU therapy for malignant brain tumors. Experimental studies and preliminary clinical results.

Authors:  J Yamashita; H Handa; Y Tokuriki; Y S Ha; S I Otsuka; K Suda; W Taki
Journal:  J Neurosurg       Date:  1983-09       Impact factor: 5.115

5.  Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma.

Authors:  M Deutsch; S B Green; T A Strike; P C Burger; J T Robertson; R G Selker; W R Shapiro; J Mealey; J Ransohoff; P Paoletti
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-06       Impact factor: 7.038

6.  Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization Grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University.

Authors:  N Roosen; J C Kiwit; E Lins; M Schirmer; W J Bock
Journal:  Cancer       Date:  1989-11-15       Impact factor: 6.860

7.  Treatment of malignant gliomas with surgery, intraarterial chemotherapy with ACNU and radiation therapy.

Authors:  F Vega; L Davila; G Chatellier; J Chiras; F Fauchon; P Cornu; L Capelle; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1992-06       Impact factor: 4.130

8.  Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme.

Authors:  F W Kreth; P C Warnke; R Scheremet; C B Ostertag
Journal:  J Neurosurg       Date:  1993-05       Impact factor: 5.115

9.  Survival and prognosis of patients with astrocytoma with atypical or anaplastic features.

Authors:  D F Nelson; J S Nelson; D R Davis; C H Chang; T W Griffin; T F Pajak
Journal:  J Neurooncol       Date:  1985       Impact factor: 4.130

10.  An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma.

Authors:  S P Stenning; L S Freedman; N M Bleehen
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

View more
  5 in total

1.  Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma.

Authors:  K Anders; G G Grabenbauer; U Schuchardt; R Fahlbusch; R Fietkau; R Sauer; P Krauseneck
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Immunophenotypic and ultrastructural validation of a new human glioblastoma cell line.

Authors:  André A Schenka; Camila M L Machado; Mariângela C Grippo; Luciano S Queiroz; Natália G M Schenka; Cristiano A Chagas; Liana Verinaud; Pierre Brousset; José Vassallo
Journal:  Cell Mol Neurobiol       Date:  2005-08       Impact factor: 5.046

3.  Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma.

Authors:  M Kochii; I Kitamura; T Goto; T Nishi; H Takeshima; Y Saito; K Yamamoto; T Kimura; T Kino; K Tada; S Shiraishi; S Uemura; T Iwasaki; J Kuratsu; Y Ushio
Journal:  J Neurooncol       Date:  2000-08       Impact factor: 4.130

Review 4.  Intra-arterial chemotherapy of primary brain tumors.

Authors:  Herbert B Newton
Journal:  Curr Treat Options Oncol       Date:  2005-11

Review 5.  Current perspectives in gliomas.

Authors:  C S Brock; M Bower
Journal:  Med Oncol       Date:  1997-06       Impact factor: 3.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.